文献速递脑血管病神经重症与神经感染

非增强CT血肿扩大标志物与andexanet反应在因子Xa抑制剂相关脑出血中的分析:ANNEXa-I试验

Non‐contrast CT Markers of Hematoma Expansion and Andexanet Response in Factor Xa Inhibitor‐Associated Intracerebral Hemorrhage: An Analysis from ANNEXa‐I Trial
RSS 订阅 · Annals of Neurology · 2026-10-22

该研究为ANNEXa-I试验的事后分析(n=434),评估因子Xa抑制剂相关脑出血中非增强CT血肿扩大标志物。至少一个标志物存在于72.1%患者,血肿扩大(≥12.5 mL或≥35%增加)发生率为31.8%。不均匀密度、低密度和黑洞征独立与血肿扩大相关。andexanet对血肿扩大的效应在各标志物亚组中基本一致。

要点

  • 因子Xa抑制剂相关脑出血中,至少一个非增强CT标志物见于72.1%患者。
  • 血肿扩大(≥12.5 mL或≥35%增加)发生率为31.8%。
  • 不均匀密度、低密度和黑洞征独立与血肿扩大相关。

核心结论

  • 非增强CT标志物有助于识别因子Xa抑制剂相关脑出血中血肿扩大高风险患者。
  • andexanet对血肿扩大的效应在各非增强CT标志物亚组中基本一致。

研究设计与样本

  • ANNEXa-I试验的事后分析,样本量n=434。

主要发现

  • 至少一个非增强CT标志物存在于72.1%的患者。
  • 血肿扩大(≥12.5 mL或≥35%增加)发生于31.8%的患者。
  • 不均匀密度、低密度和黑洞征独立与血肿扩大相关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In this post hoc analysis of the ANNEXa-I trial (n = 434), we evaluated non-contrast computed tomography (NCCT) markers of hematoma expansion (HE) in factor Xa inhibitor (FXai) –associated intracerebral hemorrhage (ICH). At least one NCCT marker was present in 72.1%, and HE (≥12.5 mL or ≥ 35% increase in hematoma volume) occurred in 31.8%. Heterogeneous density, hypodensity, and the black hole sign were independently associated with HE. The effect of andexanet on HE was generally consistent across NCCT marker subgroups. These findings support the utility of NCCT markers for identifying patients at high risk of HE in FXai-associated ICH. ANN NEUROL 2026;100:979–983

来源:Annals of Neurology,查看原文。版权归原作者所有。

引用

  1. Annals of Neurology:Non‐contrast CT Markers of Hematoma Expansion and Andexanet Response in Factor Xa Inhibitor‐Associated Intracerebral Hemorrhage: An Analysis from ANNEXa‐I Trial

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。